Big Pharma M&A set for mega year as patent expiries drive deal urgency

Biotech dealmaking is expected to have a bumper year in 2026, driven by large drugmakers acquiring assets to strengthen pipelines ahead of upcoming patent losses. The article points to an increasingly active M&A backdrop for healthcare and biotech, with patent expiration pressure acting as a key catalyst. No specific transaction values or company names are provided.

Analysis

Biotech dealmaking is expected to have a bumper year in 2026, driven by large drugmakers acquiring assets to strengthen pipelines ahead of upcoming patent losses. The article points to an increasingly active M&A backdrop for healthcare and biotech, with patent expiration pressure acting as a key catalyst. No specific transaction values or company names are provided.